drugset / Trial / NCT05150236
EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC
Phase 2
Unknown
93 enrolled
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Advanced Accelerator Applications · collabBristol-Myers Squibb · collabProstate Cancer Foundation of Australia · collabUniversity of Sydney · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This phase II study will investigate the activity and safety of radionuclide 177Lu-PSMA therapy versus 177Lu-PSMA in combination with Ipilimumab and Nivolumab in patients with metastatic castrate resistant prostate cancer (mCRPC).
Timeline
- Start
- 2022-04-29
- Primary completion
- 2024-08-31
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-PSMA-617 | Other / unclassified | 7500 mbq | — |
| Subject | Ipilimumab | Monoclonal antibody | 3 mg/kg | — |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | — |